Carnick & Kubik Group LLC raised its stake in Astrazeneca PLC (NYSE:AZN) by 8.4% during the second quarter, Holdings Channel reports. The firm owned 37,757 shares of the company’s stock after buying an additional 2,935 shares during the period. Astrazeneca PLC accounts for about 1.5% of Carnick & Kubik Group LLC’s portfolio, making the stock its 27th largest position. Carnick & Kubik Group LLC’s holdings in Astrazeneca PLC were worth $1,287,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Tompkins Financial Corp raised its position in Astrazeneca PLC by 67.0% in the first quarter. Tompkins Financial Corp now owns 3,545 shares of the company’s stock valued at $100,000 after buying an additional 1,422 shares during the period. Meeder Asset Management Inc. purchased a new position in Astrazeneca PLC during the second quarter valued at $105,000. Salem Investment Counselors Inc. purchased a new position in Astrazeneca PLC during the first quarter valued at $107,000. Tower Research Capital LLC TRC boosted its position in Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock valued at $121,000 after buying an additional 3,782 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its position in Astrazeneca PLC by 157.1% in the first quarter. Quadrant Capital Group LLC now owns 4,591 shares of the company’s stock valued at $138,000 after buying an additional 2,805 shares during the last quarter. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 29.47 on Thursday. The firm has a market cap of $74.62 billion, a price-to-earnings ratio of 19.33 and a beta of 0.74. The company has a 50 day moving average of $32.81 and a 200 day moving average of $31.41. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. Astrazeneca PLC also was the target of unusually large options trading activity on Wednesday. Investors bought 8,259 put options on the stock. This represents an increase of approximately 1,510% compared to the average daily volume of 513 put options.

Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter in the prior year, the company posted $0.83 earnings per share. The firm’s revenue was down 9.9% on a year-over-year basis. On average, equities analysts forecast that Astrazeneca PLC will post $1.85 earnings per share for the current fiscal year.

The firm also recently announced a None dividend, which will be paid on Monday, September 11th. Investors of record on Friday, August 11th will be issued a dividend of $0.44 per share. This represents a yield of 2.98%. The ex-dividend date is Wednesday, August 9th. Astrazeneca PLC’s payout ratio is 44.92%.

TRADEMARK VIOLATION NOTICE: “Carnick & Kubik Group LLC Acquires 2,935 Shares of Astrazeneca PLC (NYSE:AZN)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/carnick-kubik-group-llc-acquires-2935-shares-of-astrazeneca-plc-nyseazn/1467564.html.

Several equities analysts have weighed in on the stock. BidaskClub cut shares of Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday. Cowen and Company reiterated a “hold” rating and set a $34.00 price objective on shares of Astrazeneca PLC in a research report on Friday, July 28th. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Pareto Securities upgraded shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the stock. Astrazeneca PLC currently has an average rating of “Hold” and an average target price of $33.39.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.